Kura Oncology KURA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $67.48M+25.2% | $53.88M— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $251.07M+47.7% | $169.97M+47.5% | $115.24M+24.2% | $92.81M+9.6% | ||
| —— | $77.11M+52.5% | $50.57M— | —— | ||
| —— | —— | —— | —— | ||
| -$303.63M-57.2% | -$193.2M-16.5% | -$165.8M-18.5% | -$139.87M— | ||
| -449.9%-91.4pp | -358.5%— | —— | —— | ||
| $1.51M-6.6% | $1.62M+4.5% | $1.55M+576% | $229K— | ||
| $26.77M+17.2% | $22.85M+55.2% | $14.72M+246% | $4.25M+253% | ||
| $25.26M+19.0% | $21.23M+61.2% | $13.17M+227% | $4.03M+408% | ||
| -$278.37M-61.9% | -$171.97M-12.7% | -$152.63M-12.4% | -$135.84M— | ||
| —— | $2.02M— | $0— | $0— | ||
| -$278.67M-60.2% | -$173.98M-14.0% | -$152.63M-12.4% | -$135.84M-4.1% | ||
| -412.9%-90.1pp | -322.9%— | —— | —— | ||
| -$3.18-56.7% | -$2.03+2.4% | -$2.08-2.5% | -$2.03-3.0% | ||
| -$3.18-56.7% | -$2.03+2.4% | -$2.08-2.5% | -$2.03-3.0% | ||
| 350.3M+1.9% | 343.7M+19.0% | 288.7M+8.1% | 267.2M+0.7% | ||
| 350.3M+1.9% | 343.7M+19.0% | 288.7M+8.1% | 267.2M— | ||
| $57K— | $0— | $0— | —— | ||
| -$278.41M-61.9% | -$171.95M-17.9% | -$145.87M-2.7% | -$142.08M-7.4% | ||
| $26.77M+17.2% | $22.85M+55.2% | $14.72M+246% | $4.25M+253% | ||
| —— | —— | —— | —— | ||
| $67.48M+25.2% | $53.88M— | $0— | —— | ||
| -$303.63M-57.2% | -$193.2M-16.5% | -$165.8M-18.5% | -$139.87M— | ||
| -$302.6M-57.3% | -$192.35M-16.6% | -$164.96M-18.6% | -$139.11M— | ||
| -$302.6M-57.3% | -$192.35M-16.6% | -$164.96M-18.6% | -$139.11M— | ||
| -448.4%-91.4pp | -357%— | —— | —— | ||
| -$303.63M-57.2% | -$193.2M-16.5% | -$165.8M-18.5% | -$139.87M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kura Oncology's revenue?
- Kura Oncology (KURA) generated $71.6M in revenue over the trailing twelve months, up 31.4% year over year.
- Is Kura Oncology profitable?
- Kura Oncology is not currently profitable: it reported a net loss of $294.6M over the trailing twelve months, a -411.2% net margin.
- What is Kura Oncology's earnings per share?
- Kura Oncology's diluted EPS over the trailing twelve months is $-3.35.
- Where does Kura Oncology's income statement data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
